The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

We can see that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) does use debt in its business. But is this debt a concern to shareholders? Debt assists a business until the business has trouble paying it ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts ...

Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across ...

Investors might want to bet on Alnylam Pharmaceuticals (ALNY), as earnings estimates for this company have been showing solid ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent ...

Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $253.55.

Alnylam Pharma (ALNY) Company Description: Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

Alnylam Pharmaceuticals (ALNY) shares surge 16% as it raises 2025 revenue outlook and posts strong Q3 results. Read more here.

Contacts Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 ...